Simon Sturge Appointed as Non-Executive Director at Galapagos
20-09-2023 Galapagos announced that Simon Sturge has joined as an independent non-executive director on the Executive Board. He takes the position previously held by Mary Kerr, who resigned on September 18.
Simon Sturge has over 40 years of experience in the international biotech and pharmaceutical sector, holding leadership positions at companies such as Merck KGaA and Boehringer Ingelheim. He was the CEO of Kymab (now Sanofi) and Celltech Biologics (now Lonza), and is a co-founder of Ribotargets (now Vernalis). Currently, Sturge serves as the Executive Chair at Mediar Therapeutics and Non-Executive Chair at MoonLake Immunotherapeutics and Precerix.
Paul Stoffels, CEO and Chairman of Galapagos, stated, "On behalf of the Galapagos Executive Board, I am very pleased to welcome Simon Sturge to our Board. Simon is an experienced leader in the field of life sciences and brings global expertise in M&A, business transformations, and commercial activities. His extensive expertise in the production of biological medicines, gained through his leadership roles over decades at Celltech Biologics, Merck KGaA, and Boehringer Ingelheim, brings additional strategic insights to our board and will be invaluable in positioning our company for long-term value creation."